2 microscopy as diagnostic, removal of children protected by maternal antibodies (age <= 6months), removal of 3 areas with a BCG coverage >=90% and a combination of the latter two were used as sensitivity analyses of the 4 association between BCG vaccination and malaria prevalence. All results are depicted as adjusted odds ratios 5 ±95% CI retrieved from multilevel logistic regression analyses with 4 levels (child, cluster, region and country) 6 with correction for age, birth order, sex, twin, place of delivery, size at birth, preceding birth interval, weight-for- Calmette-Guérin. **P-value <0.01, ***P-value <0.001. 
Country (ISO code)
Brand The resulting relative risks are only an approximation of the true relative risks. Based on these risks the absolute 52 reduction in malaria prevalence was calculated for the non-vaccinated group and the total population. The latter 53 was converted to the percentage of reduction in malaria prevalence possible if the association between BCG and 54 malaria would be attributable to the non-specific effects of BCG. This resulted in possible reductions of 1-3% for 55 the overall population, but up to 10% for individual regions with low BCG coverage.
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